StreetAlpha.app
Home › Stocks › OPK

Opko Health, Inc. (OPK)

Healthcare
$1.57
▼ −2.48%
LAST CLOSE · NOV 20

OPKO Health sells NGENLA growth hormone treatment, Rayaldee kidney disease treatment and specialty lab tests for doctors and patients. It last closed at $1.57 on Nov 20, down 2.48% on the day. The next earnings report for OPK is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, OPK reported EPS of -$0.07 on revenue of $65.4M, with revenue up 15.9% from a year ago. Over its last 8 reports the stock moved an average of 7.6% the session after earnings. Over the last 12 months OPK insiders bought $1.6M of stock on the open market and sold $25K, according to SEC Form 4 filings.

AI Auto Pilots
Is OPK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OPK.

Key Stats

Last 12 months
Results
Revenue
$654.1M
+90.8% vs a year ago
Net income
−$148.1M
−22.6% margin
EPS (diluted)
−$0.20
Free cash flow
−$135.3M
−20.7% margin
Valuation
Market cap
$1.2B
742.5M shares
P/E
–
No P/E while losing money
Price to sales
1.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$384.0M
At Sep 30
Debt
$477.4M
At Sep 30
Shareholder equity
$1.1B
Buybacks
$41.9M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.8B$1.8BFY2021FY2022: $1.0B$1.0BFY2022FY2023: $863.5M$863.5MFY2023FY2024: $713.1M$713.1MFY2024FY2025: $606.9M$606.9MFY2025

From OPK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
-$0.07
Quarter ended Sep 2026
Year ago EPS
$0.03
−333.3% on a GAAP basis
Revenue
$65.4M
+15.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.01Dec '24Mar 2025: -$0.10Mar '25Jun 2025: -$0.19Jun '25Sep 2025: $0.03Sep '25Dec 2025: -$0.04Dec '25Mar 2026: -$0.07Mar '26Jun 2026: -$0.01Jun '26Sep 2026: -$0.07Sep '26Latest -$0.07
Revenue by quarter
Dec 2024: $183.6MDec '24Mar 2025: $150.0MMar '25Jun 2025: $156.8MJun '25Sep 2025: $56.4MSep '25Dec 2025: $148.5MDec '25Mar 2026: $124.2MMar '26Jun 2026: $163.6MJun '26Sep 2026: $65.4MSep '26Latest $65.4M
How OPK moved after its last 8 reports
Average move the session after a report ±7.6%
Nov 4, 2026After the close−1.1%
Jul 27, 2026After the close+33.1%
Apr 28, 2026After the close−8.3%
Feb 26, 2026After the close0.0%
Oct 29, 2025After the close+2.1%
Jul 31, 2025After the close−7.0%
Apr 30, 2025After the close−2.2%
Feb 27, 2025After the close+6.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OPKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on OPK
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OPK

Technical Analysis

OPK · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 7% below its 20 day and 2% below its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the Pivot S1 at $1.54, and the nearest resistance the Pivot at $1.58.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 5.4%/day
Key levels
$1.8652 week high+18.5%
$1.6720 day average+6.4%
$1.6150 day average+2.5%
$1.61Pivot R1+2.5%
$1.61Swing high (Jun 26)+2.5%
$1.58Pivot+0.6%
$1.57Last close
$1.54Pivot S1−1.9%
$1.50100 day average−4.5%
$1.48Swing low (Jun 30)−5.7%
$1.37200 day average−12.7%
$0.9852 week low−37.6%
Indicators
RSI (14)42.62Middle of its rangeNeutral
MACD0.01Below its signal lineBearish
Stochastic18.4Near the bottom of its rangeOversold
ADX (14)22.1Weak trend
Williams %R-92.1Oversold below −80, overbought above −20Oversold
CCI (20)-145.9Oversold below −100, overbought above 100Oversold
Rate of change−9.3%Change over 10 sessionsBearish
ATR (14)$0.09Typical daily range, 5.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for OPK

What happened before

See how OPK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OPK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OPK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OPKHow many large options trades hit OPK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

OPK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼82 buying vs 99 selling
  • ●Held by funds -0.1 pts
  • ●Funds holding +2
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding226224+0.9%
In funds' top 1000–
Held by funds27.2%27.3%−0.1 pts
New / increased30 / 5222 / 75−15.5%
Reduced / sold out75 / 2450 / 31+22.2%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OPK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OPK Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$1.6M3 buys · 2 insiders
Sold$25K1 sale · 1 insider
2026-03 bought $11K2026-11 sold $25KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 5John A PaganelliDirectorSale13,601$1.81$25K
Mar 20John A PaganelliDirectorBuy10,000$1.14$11K
Nov 21, 2025Frost Gamma Investments Trust10% ownerBuy580,000$1.33$770K
Nov 20, 2025Frost Gamma Investments Trust10% ownerBuy580,000$1.33$772K
Nov 19, 2025Frost Gamma Investments Trust10% ownerBuy580,000$1.31$761K
Nov 18, 2025Frost Gamma Investments Trust10% ownerBuy533,300$1.28$681K
Every insider buy and sale for OPK over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OPK insider trades →

From SEC Form 4 filings by OPK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OPK is in one of them and how their past OPK trades turned out.

OPK in the AI portfolios
Loading…

OPK News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OPK in an article yet. Here's the latest on the wider market.

OPK in the news

OPK Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Oct 3
Who traded OPK · since 2017
Latest 3 filings
$1K – $15KTraded Sep 26, 2017Filed Oct 3, 2017
$1K – $15KTraded Mar 2, 2017Filed Mar 2, 2017
$1K – $15KTraded Feb 7, 2017Filed Feb 7, 2017
PersonTypeAmountTradedFiledDelay
Carlos CurbeloR · FLBuy$1K – $15KSep 26, 2017Oct 3, 20177 d
Carlos CurbeloR · FLBuy$1K – $15KMar 2, 2017Mar 2, 20170 d
Carlos CurbeloR · FLBuy$1K – $15KFeb 7, 2017Feb 7, 20170 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Opko Health

OPKO Health is a healthcare company based in Miami, Florida. It sells NGENLA, a weekly growth hormone treatment for children, and Rayaldee, a treatment for secondary hyperparathyroidism in adults with chronic kidney disease. Its laboratory business provides clinical and women's health testing in New York and New Jersey, along with the 4Kscore prostate cancer test, which is offered across the United States. The company is also developing therapies for cancer and infectious disease.

Headquarters
Miami, FL